Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBER: VAY736 in Autoimmune Hepatitis
jRCT2080223740Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of ianalumab in autoimmune hepatitis (AIH) (4 arms), sponsored by Novartis. Started Dec 2017; status: completed.
02
Drugs
ianalumab
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on jRCT2080223740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223740.